A genus of lipophilic basidiomycete yeasts that is the dominant fungus on human skin and has recently been recognized as a significant component of the gut mycobiome. M. restricta, M. globosa, and M. furfur are the primary species. Originally studied as the cause of dandruff and seborrheic dermatitis, Malassezia has emerged as an unexpectedly important player in gut dysbiosis, particularly in cardiovascular disease and hypertension.
Skin Commensal Role
- Colonizes lipid-rich skin sites (scalp, face, chest, back) where it metabolizes host sebum triglycerides via secreted lipases, releasing unsaturated fatty acids (oleic acid) that can trigger inflammation in susceptible individuals.
- M. restricta is the primary causative agent of dandruff and seborrheic dermatitis through lipase-mediated oleic acid release and subsequent inflammation.
- M. furfur causes pityriasis versicolor (skin depigmentation) and can cause systemic fungemia in neonates receiving lipid parenteral nutrition.
- The genus is uniquely lipid-dependent -- it lacks the genes for de novo fatty acid synthesis and must acquire lipids from its environment.
Gut Mycobiome Presence
- Despite being considered a skin organism, Malassezia is consistently detected in gut mycobiome surveys, likely arriving via ingestion and possibly establishing transient or semi-permanent colonization.
- In the gut, Malassezia interacts with bacterial communities: negatively correlated with Bifidobacterium, roseburia, and ruminococcus in IBD patients [huang 2024 gut fungi ibd colorectal cancer].
- Positively correlated with candida albicans and Aspergillus in ASD gut mycobiome [strati 2017 altered gut microbiota mycobiota asd].
Enrichment in Cardiovascular Disease
Hypertension
- Malassezia abundance increases progressively from normotensive to pre-hypertensive to hypertensive subjects (significant between HTN and NT) [zou 2022 mycobiome dysbiosis hypertension light chains].
- Positively associated with immunoglobulin light chain kappa in pre-HTN (r=0.510, P=0.044) and both kappa and lambda in HTN, suggesting immune activation by Malassezia antigens.
- Fungal dysbiosis detected already at the pre-hypertension stage, suggesting mycobiome changes precede clinical hypertension.
Broader Cardiometabolic Disease
- Enriched in HTN+CKD comorbidity (18.71% of fungal community vs lower in controls) [qiu 2023 gut mycobiome hypertension ckd].
- Increased in atherosclerotic CVD alongside Exophiala, Penicillium, and Wallemia [wei 2025 gut mycobiome cardiometabolic disease].
- Also enriched in obesity: M. restricta increased in obese individuals.
Immunomodulatory Properties
- Malassezia cell wall components (mannans, beta-glucans) activate Dectin-1, Dectin-2, and TLR2 on innate immune cells.
- Produces arachidonic acid metabolites via phospholipase activity that can modulate local inflammation.
- Immunoglobulin light chain dysregulation associated with Malassezia enrichment in hypertension suggests a novel immune-fungal-cardiovascular axis.
- In IBD, Malassezia may activate CARD9-dependent immune pathways in genetically susceptible individuals.
Oral-Gut-Skin Axis
- Malassezia presence in three body niches (skin, oral cavity, gut) raises the possibility of a fungal oral-gut-skin axis.
- Skin Malassezia infections may seed gut colonization via ingestion; conversely, gut immune responses to Malassezia may influence skin disease.
- This multi-niche colonization is relevant to systemic diseases like cardiovascular disease where both gut and skin microbiome alterations have been documented.
Key Metabolites
- Lipase products -- oleic acid and other unsaturated fatty acids from sebum/lipid metabolism; inflammatory triggers.
- Indole derivatives -- some Malassezia species produce tryptophan-derived metabolites that act as aryl hydrocarbon receptor (AHR) ligands, modulating skin and gut immune responses.
- Arachidonic acid metabolites -- phospholipase-derived inflammatory mediators.
Connections
- cardiovascular disease -- enriched in hypertension and atherosclerosis; immunoglobulin light chain associations
- chronic kidney disease -- enriched in HTN+CKD comorbidity
- autism spectrum disorder -- detected in ASD gut mycobiome; correlated with Candida
- candida albicans -- positively correlated; both enriched in disease mycobiomes
- saccharomyces -- co-occurring in gut mycobiome; both altered in CVD
- inflammation -- lipase-mediated oleic acid release; Dectin-1/TLR2 activation
- dysbiosis -- fungal dysbiosis precedes clinical hypertension
- gut metal microbiome -- indirect metal interactions; heavy metals may shift bacterial communities that normally suppress Malassezia
- roseburia -- negatively correlated in IBD; bacterial-fungal competitive dynamics
- biofilm -- forms biofilms on skin; potential for gut biofilm formation
- oxidative stress -- arachidonic acid metabolites promote oxidative inflammatory damage